Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Schisandra chinensis

Plain-language summaryIntrigue 48 / 100

Schisandra (Chinese magnolia vine) berry is an adaptogen used in traditional Chinese medicine for stress, fatigue, and liver support. The lignans class drives the activity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

25/100

Well-characterized adaptogen lignan with diffuse mechanism and thin human evidence, outcompeted in every niche

Look, Schisandra chinensis has been in the Chinese pharmacopeia for centuries, and the bench literature has expanded correspondingly. But expanded doesn’t mean improved. The active constituents, the schizandrin lignans (schizandrin A, B, C, gomisin A, gomisin N, and a handful of others), are reasonably well characterized chemically, and theres a modestly sized body of work on hepatoprotection in rodent liver injury models. That’s the ceiling of the story, and it’s not a high ceiling.

The mechanism picture is diffuse to the point of frustration. Nrf2 pathway activation, antioxidant effects, HPA axis modulation, vague adaptogenic stress-tolerance framing: these are the kinds of multi-mechanism claims that look comprehensive on a monograph page but are hard to operationalize at the bench. The CYP3A induction activity is probably the most mechanistically specific angle, and that’s primarily relevant as a drug interaction liability, not a productive research target in itself.

The differentiation problem is real. Schisandra sits in a crowded adaptogen space alongside Rhodiola rosea, Withania somnifera, Eleutherococcus senticosus, and Panax ginseng. Each of those alternatives has at least one distinctive mechanistic claim or a more developed trial base. Rhodiola has the SHR-5 extract work and the partial MAO inhibition angle. Ashwagandha has the KSM-66 RCT series and a consistent cortisol signal. Schisandra’s hepatoprotective niche is real but contested by compounds with significantly better evidence: silymarin, TUDCA, NAC. On no single dimension does Schisandra clearly win.

On translational signal, the honest picture is thin. Human trials exist but are small, poorly blinded, and concentrated in Eastern European and Chinese research groups without independent replication. Effect sizes in stress-tolerance and endurance outcomes are modest and inconsistently reported across studies. We dont think the preclinical signal is fabricated; the schizandrins do interesting things in hepatocyte injury models. But the bench-to-clinic arrow is weak, and the question of whether those rodent outcomes generalize to meaningful human endpoints remains open in a way that’s not particularly exciting to work on right now.

For bench utility, Schisandra isn’t zero. If you’re running a lignan pharmacokinetics panel, building a CYP3A induction comparison, or designing a comparative adaptogen study that needs a reference compound, it has a slot. But thats a narrow role. A researcher designing a program around Schisandra specifically would struggle to justify that choice against the available alternatives, and we think most serious investigators already know that. The score reflects it.

Novelty

22

Mechanism promise

28

In-category differentiation

25

Evidence quality

28

Translational signal

25

Research bench value

22

Rationale Schisandra scores low on novelty (decades-old herb in a crowded adaptogen category) and differentiation (no clear superiority over Rhodiola, ashwagandha, or silymarin on any key metric); the schizandrin lignan profile is chemically interesting but translational evidence is thin and concentrated in single-consortium work without independent replication, placing the raw calculated score well below the OTC-herb cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Chinese magnolia vine berry adaptogen

A Chinese berry traditionally used as the ‘five flavors fruit’ for endurance, mental clarity, and hepatoprotection, characterized by schizandrins.

Abstract

Schisandra chinensis (Wu Wei Zi, “five flavors fruit”) is a climbing vine from China and Russia whose berries have been used for endurance, mental clarity, hepatoprotection, and longevity. The active constituents are lignans called schizandrins (schizandrin, gomisin A, gomisin N, and others). Modest hepatoprotective effects in liver injury models, antioxidant effects, and stress-tolerance effects have been documented. The schizandrins are CYP3A inducers, which has clinical drug interaction implications. Doses are typically 500 to 2000 mg per day of berry extract.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-115Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Liraglutide

Plain-language summaryIntrigue 80 / 100

Liraglutide, sold as Victoza and Saxenda, was the first daily GLP-1 receptor agonist approved for both diabetes (Victoza) and weight loss (Saxenda). It paved the way for the entire GLP-1 obesity drug class. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

The founding daily GLP-1 agonist, now eclipsed by semaglutide on nearly every metric that matters

Look, liraglutide earns its place in the library as the compound that first proved GLP-1 receptor agonism could sustain meaningful weight loss in a real clinical setting. The SCALE obesity program, the LEADER cardiovascular outcomes trial, FDA approvals for both T2DM and chronic weight management: the evidence base is legitimate and well-replicated. The problem is that “legitimate and well-replicated” now describes a 2010-era compound that’s been clearly outclassed in nearly every direction that matters to a bench investigator today.

The mechanism is GLP-1R agonism, single-target, well-understood. The palmitoyl fatty acid chain and albumin-binding strategy for extending half-life to roughly 13 hours was genuinely clever engineering at the time, enabling once-daily subcutaneous dosing when that was the frontier. But the same albumin-binding logic, applied to a longer chain and a refined backbone, gave Novo Nordisk semaglutide: weekly dosing, roughly double the weight-loss efficacy, a cardiovascular mortality signal, a renal protection signal, and eventually oral bioavailability. The engineering that made liraglutide work also showed researchers exactly how to do it better.

On differentiation, this is where liraglutide really struggles. It’s not competitive with semaglutide on efficacy. It’s not competitive with tirzepatide on mechanism breadth. Within the daily-dosing GLP-1 space it has no surviving advantage: dulaglutide is weekly, exenatide extended-release is weekly, semaglutide oral is approved. Daily dosing is a liability, not a feature. Cross-program comparisons between the SCALE and STEP trial families have formalized the hierarchy, with semaglutide delivering roughly 15-17% body weight reduction versus liraglutide’s ~8% in the SCALE trials.

What liraglutide retains is real research utility as a reference compound. If youre running a GLP-1R biology study, liraglutide is a well-characterized probe with known receptor-binding affinity constants, decades of pharmacokinetic data, and a predictable safety profile at research doses. It serves as a positive control in screens, and the LEADER cardiovascular data provides a concrete clinical comparator for any new compound trying to demonstrate CV benefit in the GLP-1 class. Thats genuine bench value, but it’s the bench value of an established reference tool, not an active investigation target.

We think liraglutide belongs in the library primarily as context: what the first generation of long-acting GLP-1R agonists looked like, and why the class evolved the way it did. For a researcher trying to understand GLP-1 biology deeply, it’s worth knowing. For a researcher trying to identify the next compelling metabolic target, it mostly points toward semaglutide, tirzepatide, or the triple agonists further along the development curve. Honest assessment: this is a workhorse that has already done its most important work.

Novelty

22

Mechanism promise

45

In-category differentiation

15

Evidence quality

78

Translational signal

70

Research bench value

55

Rationale Liraglutide defined the GLP-1 obesity category and carries genuinely strong evidence (SCALE program, LEADER CV outcomes trial), but single-target GLP-1R agonism at daily dosing is now a legacy profile; semaglutide’s superior efficacy and weekly schedule have made liraglutide a historical reference rather than a live research priority, and differentiation scores accordingly low.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Daily GLP-1 receptor agonist

A daily-dosing GLP-1 analog FDA-approved as Victoza (T2DM, 2010) and Saxenda (obesity, 2014); the predecessor of semaglutide.

Abstract

Liraglutide (Victoza, Saxenda; CAS 204656-20-2; molecular weight 3751.20) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA for T2DM (2010) and obesity (2014). The compound features a 16-carbon fatty acid (palmitoyl) chain attached to lysine 26 via a glutamic acid spacer, enabling reversible albumin binding for extended half-life of approximately 13 hours, supporting once-daily subcutaneous dosing. Liraglutide was the first GLP-1 agonist approved for chronic weight management. Approved doses are 0.6 to 1.8 mg daily for T2DM and titrated to 3 mg daily for obesity.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-132Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Melatonin

Plain-language summaryIntrigue 65 / 100

Melatonin is the sleep hormone produced by the pineal gland in response to darkness. Supplementation is used for circadian rhythm disorders, jet lag, and sleep onset. The optimal dose is much lower than typically sold (0.3 mg, not 5-10 mg). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

Canonical circadian probe with real evidence, but biologically settled and low on the novelty frontier

Look, melatonin is one of those compounds that scores well on evidence precisely because its research era is basically over. The MT1 and MT2 receptor pharmacology is fully mapped. The circadian phase-shifting literature goes back decades. Multiple well-designed RCTs confirm modest but real effects on sleep onset and jet lag. If you’re scoring “is there real data,” melatonin clears that bar handily. But that’s not what this rubric is asking.

The question is whether a serious bench scientist should be spending time here right now. And the honest answer for most investigators is no. The MT1/MT2 system is not an open frontier. The endogenous synthesis pathway from tryptophan through serotonin is textbook. The antioxidant angle gets mentioned in abstracts but the concentrations required for meaningful ROS scavenging in vivo are so far above physiological range that it doesn’t generate clean mechanistic insight. We’ve been down that road.

Where melatonin holds some residual bench value is as a reference ligand and timing tool for circadian entrainment experiments. If you’re studying chronobiology or trying to establish light-dark cycle baselines in rodent models, melatonin is what you reach for. Ramelteon is more selective at MT1/MT2, which makes it a sharper tool in some assay contexts, but melatonin’s endogenous status gives it ecological validity you dont get from a synthetic agonist. That’s a real but narrow argument for its continued utility.

The oncology literature is worth flagging as the one place where melatonin’s story isnt fully written. There’s a body of work, some of it multi-lab, pointing at adjunctive roles in solid tumor models, possibly through circadian disruption pathways. The Lissoni group’s clinical work from the 90s and 2000s is often cited but never quite confirmed at the scale or rigor you’d want. This is probably the most defensible reason a researcher might take a fresh look, but even here the signal hasn’t broken into mainstream oncology practice and the mechanism remains contested.

What we dont like: the gap between how widely this compound is discussed and how little genuinely open research territory remains. Most melatonin papers in 2025 are confirmatory or applied, not mechanistically generative. The pharmacokinetic variability at oral doses is real and relevant for study design, but it’s a methodological nuisance, not a scientific frontier. If your lab is doing circadian biology, keep a bottle on the shelf. If you’re looking for a research program, there are better places to build one.

Novelty

18

Mechanism promise

22

In-category differentiation

35

Evidence quality

62

Translational signal

58

Research bench value

52

Rationale Melatonin scores naturally low on novelty and mechanism because MT1/MT2 agonism and circadian phase-shifting are among the best-characterized pharmacology in all of chronobiology; evidence is actually solid by supplement standards, but the science is so settled it produces little frontier value for a bench investigator in 2026.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous indolamine hormone

An endogenous pineal hormone synthesized from serotonin, the master circadian regulator and a widely-used sleep supplement.

Abstract

Melatonin (N-acetyl-5-methoxytryptamine; CAS 73-31-4; molecular formula C13H16N2O2; molecular weight 232.28) is an endogenous indolamine synthesized in the pineal gland from serotonin via N-acetylation and 5-methoxylation. Endogenous melatonin secretion peaks during darkness and is the principal hormonal signal of biological night. Supplementation is widely used for sleep onset, jet lag, and shift work sleep. Mechanism is MT1 and MT2 melatonin receptor agonism; the compound also has direct antioxidant activity. Pharmacokinetics: plasma half-life 30 to 50 minutes; oral bioavailability variable (15 to 50 percent). Doses for sleep are 0.3 to 5 mg orally 30 to 60 minutes before bedtime; lower doses (0.3 to 1 mg) may be more physiologically appropriate but commercial supplements typically provide higher doses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-149Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Theacrine

Plain-language summaryIntrigue 52 / 100

Theacrine is a methylxanthine alkaloid found in kucha tea. It produces stimulant effects similar to caffeine but with reportedly less tolerance development and longer duration. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

A caffeine analog with a modest tolerance story and industry-dominated evidence base

Look, theacrine is basically caffeine with two extra methyl groups and a slower absorption curve. That sentence contains almost everything you need to know about its research profile. The compound is 1,3,7,9-tetramethyluric acid, found naturally in kucha tea (Camellia kucha) and some yerba mate, and it became commercially interesting when Compound Solutions started selling it as TeaCrine around 2014. Since then it has accumulated a small but real published literature. The problem is that almost all of it traces back to the same small circle of labs with funding ties to the commercial product.

The mechanism story isnt wrong. Adenosine receptor antagonism is real pharmacology, and the structural difference from caffeine (the 7,9-methylation pattern) likely does produce the slower onset and the reportedly attenuated tolerance development that the TeaCrine marketing leans on. Kuhman et al. 2015 and Ziegenfuss et al. 2017 both showed some signal on subjective energy and mood. We dont dismiss those results. But “some signal on subjective energy in small industry-sponsored trials” is a long way from a research program worth prioritizing. Effect sizes are modest, the studies are underpowered, and independent replication outside the Compound Solutions orbit is thin.

The tolerance angle is actually the only thing that gives theacrine any differentiation over caffeine as a research object. The idea that the additional methylation changes receptor kinetics in a way that slows tolerance is interesting mechanistically. But if you want to study adenosine receptor tolerance, you already have caffeine, which has 50 years of literature and is the de facto probe for this receptor family. Theacrine doesnt let you answer a question you couldnt answer with caffeine; it mostly gives you a marginally different pharmacokinetic profile and a commercial incentive to publish positive results.

We think theacrine occupies a real but narrow niche: its useful for performance nutrition research where the specific question is “is there a methylxanthine with lower tolerance liability than caffeine” and you need a test compound. That is a legitimate question. Its just not a high-priority one for most bench programs. The translational signal in humans is real but modest, the evidence quality is constrained by industry capture, and the compound lacks the kind of novel mechanism or strong independent replication that would push it up the priority stack. Honestly, if you’re building a CNS stimulant research program, caffeine + a good tolerance protocol answers more questions with better-validated tools. Theacrine is worth knowing about; it isnt worth centering a program around.

Novelty

30

Mechanism promise

28

In-category differentiation

35

Evidence quality

30

Translational signal

35

Research bench value

20

Rationale Theacrine scores low primarily because its mechanism is effectively adenosine receptor antagonism with a slightly different methyl pattern, offering little probe value beyond what caffeine already provides. The tolerance-development differentiation story is real but mostly validated by Compound Solutions-funded studies with small N, which caps both evidence quality and translational confidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Methylxanthine / kucha tea alkaloid

A methylxanthine present in kucha tea (Camellia kucha) with caffeine-like CNS effects but reduced tolerance development.

Abstract

Theacrine (1,3,7,9-tetramethyluric acid; CAS 2309-49-1) is a methylxanthine alkaloid present in kucha tea (Camellia kucha) and yerba mate. The compound has structural similarity to caffeine but with two additional methyl groups that produce a distinct pharmacology. Theacrine acts as an adenosine receptor antagonist (similar mechanism to caffeine) but with slower onset (peak effect at 1.5 to 2 hours) and reportedly slower tolerance development. The compound is sold as TeaCrine (Compound Solutions) for performance and energy applications. Doses are typically 100 to 300 mg per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-164Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Boswellia serrata

Plain-language summaryIntrigue 55 / 100

Boswellia serrata is the source of frankincense gum resin. Boswellic acids inhibit 5-lipoxygenase and produce anti-inflammatory effects, particularly in osteoarthritis and inflammatory bowel disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

Mature Ayurvedic anti-inflammatory with real but unremarkable 5-LOX signal and modest clinical effect sizes

Cap applied Common OTC food/herb — max 35

Look, Boswellia serrata is the kind of compound that shows up in every supplement stack but rarely makes it into a serious investigator’s notebook. The tree resin has been used in Ayurvedic practice for centuries, and the active fractions, boswellic acids with acetyl-11-keto-beta-boswellic acid (AKBA) as the most pharmacologically characterized constituent, do have a real mechanism: selective 5-lipoxygenase inhibition that reduces leukotriene synthesis without the gastrointestinal liability of COX pathway blockade. That selectivity is honestly the most interesting thing about it, and it was genuinely exciting when first characterized in the early 2000s.

The clinical literature is real. There are multiple randomized trials in osteoarthritis, including the H15 extract trials and the Loxin (5-Loxin) program, plus a handful of IBD studies, and the signal holds up across labs better than you’d expect from an herbal compound. Effect sizes are modest: functional improvement in OA symptoms, some signal in Crohn’s and ulcerative colitis. It’s not anecdote. But it’s also not surprising anymore, and the field has largely moved on from treating 5-LOX inhibition as a particularly exciting new axis.

Here’s the issue for a 2025 research program. Pharmaceutical 5-LOX inhibitors like zileuton give you cleaner pharmacology if you actually need to probe the leukotriene pathway. The boswellic acid literature is heavily standardized-extract-centric, which makes mechanistic bench work messy. You’re working with a mixture, not a defined compound. AKBA can be isolated, and theres a subset of papers doing exactly that, but the tool-compound story is complicated by absorption issues (poor oral bioavailability of boswellic acids is well-documented) and the absence of well-validated cellular assays that cleanly attribute effects to 5-LOX vs. other targets AKBA has been proposed to hit, including cathepsin G and microsomal prostaglandin E synthase 1.

We dont think this is a bad compound. It’s clearly doing something useful in joint and gut inflammation models. But the novelty bar is gone, the mechanism is fully characterized, and the clinical signal, while real, isnt pushing any frontier. If youre looking for a productive anti-inflammatory research target in 2025, there are better entries where the mechanism is fresher and the translational picture is still being written. Boswellia earned its place in the historical literature; it just doesnt have much left to teach us at the bench right now.

Novelty

20

Mechanism promise

35

In-category differentiation

30

Evidence quality

55

Translational signal

52

Research bench value

28

Rationale Boswellic acids have a legitimate 5-LOX mechanism and replicated clinical signal in OA and IBD, but the compound is decades old, the mechanism is fully characterized, and better defined tool compounds exist for leukotriene pathway probing; the OTC herb cap binds at 35 over a calculated 36.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Frankincense gum resin / boswellic acids

An Indian frankincense resin containing boswellic acids with selective 5-lipoxygenase inhibition for inflammatory conditions.

Abstract

Boswellia serrata (Indian frankincense) is a tree resin used in Ayurvedic medicine for inflammatory conditions, particularly osteoarthritis and inflammatory bowel disease. Active constituents are boswellic acids (acetyl-11-keto-beta-boswellic acid, AKBA, being the most pharmacologically characterized). Mechanism is selective inhibition of 5-lipoxygenase (5-LOX), reducing leukotriene synthesis. Doses are typically 300 to 1200 mg of standardized extract (typically standardized to 65 to 75 percent boswellic acids or to specific AKBA content) per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-180Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Niacin (Nicotinic Acid)

Plain-language summaryIntrigue 55 / 100

Niacin (nicotinic acid) is vitamin B3 in its acid form, distinct from nicotinamide. It causes flushing (a vasodilatory side effect) at therapeutic doses. Used historically for high cholesterol and as a NAD+ precursor. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

27/100

Mature vitamin B3 with real lipid biology but outclassed in every modern research context

Cap applied Generic vitamin cap (28)

Look, niacin is vitamin B3. It has been in the pharmacopoeia since before most working scientists were born, and thats not a knock on it as a nutrient. It’s just the honest truth about where it sits in the research conversation in 2026.

The high-dose lipid story had real momentum from the 1970s through the early 2000s. Niacin genuinely lowers LDL, raises HDL, and reduces triglycerides via hepatic VLDL synthesis suppression, and that mechanism is not contested. The problem is that AIM-HIGH (2011, NEJM) and HPS2-THRIVE (2014, NEJM) both showed that adding extended-release niacin to statin therapy produced no reduction in major cardiovascular events. The lipid numbers moved; the outcomes didn’t. That’s a decisive translational failure for the indication that drove decades of clinical interest, and the field has largely moved on.

The flushing mechanism is actually the more pharmacologically interesting angle. Prostaglandin D2 release from Langerhans cells via GPR109A activation is well-defined, and niacin remains the canonical GPR109A agonist. Some groups have used this as a dermal inflammation probe. Laropiprant, the DP1 receptor antagonist that Merck co-formulated to suppress flushing, generated its own research trail before that combination was pulled for safety reasons. So there’s a narrow niche-probe story here, but it’s genuinely narrow.

The NAD+ precursor angle is where you’d hope niacin might find modern relevance, but it loses badly to NMN and NR in that competition. Nicotinamide riboside and mononucleotide bypass the rate-limiting NAMPT step more efficiently and without triggering GPR109A. If your research program is about NAD+ biology, sirtuin activation, mitochondrial function, or aging, niacin isnt the compound you reach for. The frontier precursor literature is being built on those other forms, not on plain nicotinic acid.

What we don’t like: there’s no open research question in 2026 where plain niacin is the tool of choice. It’s either historically important in a space where outcomes data disappointed, trivially established as a nutrient, or outclassed as a NAD+ precursor. The niacinamide distinction adds a layer of formulation complexity without opening new research directions.

What we’ll give it: the GPR109A agonism reference-probe utility is real for labs specifically studying that receptor or prostaglandin-mediated skin biology. The evidence base is large and the pharmacology is clean. But the evidence base is large because the compound is old, not because the open questions are exciting. For a library designed to surface compounds worth bench time right now, niacin earns a slot as a reference standard and historical marker, not as a priority target.

Novelty

10

Mechanism promise

18

In-category differentiation

12

Evidence quality

68

Translational signal

42

Research bench value

22

Rationale Plain nicotinic acid is an essential vitamin with well-understood mechanisms; the high-dose dyslipidemia indication is mature and outcome-trial-disproven for CV benefit, and the NAD+ precursor angle is dominated by NMN and NR. No novel indication with real signal exists that would lift the generic-vitamin cap, and the raw weighted score (approx 27) falls within the cap anyway.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Vitamin B3 / NAD+ precursor

Vitamin B3 used at high doses for dyslipidemia and at low doses as an essential nutrient and NAD+ precursor.

Abstract

Niacin (nicotinic acid; CAS 59-67-6; molecular formula C6H5NO2; molecular weight 123.11) is vitamin B3, used at low doses (10 to 30 mg/day) as an essential nutrient and NAD+ precursor, and at high doses (1 to 3 grams per day) for dyslipidemia management. The high-dose niacin lipid effect (LDL reduction, HDL elevation, triglyceride reduction) is mediated through hepatic VLDL synthesis effects. The flushing response (cutaneous vasodilation, warmth, itching) at high doses is a prostaglandin-mediated effect that can be mitigated by aspirin pre-treatment or by use of immediate-release formulations with gradual titration. Niacinamide (nicotinamide) does not produce flushing but lacks the lipid effects.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-197Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vilazodone

Plain-language summaryIntrigue 53 / 100

Vilazodone (Viibryd) is an antidepressant from Forest Pharmaceuticals, approved in 2011, designed to do two things at once: block the serotonin pump like an SSRI and also directly partially activate the 5-HT1A serotonin receptor. The theory was that hitting 5-HT1A directly would short-circuit the slow autoreceptor desensitization process that normally delays SSRI response by several weeks. In practice the speed advantage in trials has been modest, and the drug has not displaced standard SSRIs as a first-line option. It does have somewhat lower rates of sexual dysfunction than SSRIs, which is its main practical selling point. Must be taken with food (at least 500 calories) for adequate absorption. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

FDA-approved dual-mechanism antidepressant with real pharmacology but limited frontier research appeal

Look, vilazodone is a real drug with a real rationale. The idea behind it is sound: block SERT to raise synaptic serotonin, and simultaneously activate 5-HT1A autoreceptors directly so you dont have to wait weeks for those autoreceptors to desensitize on their own. That delay is one of the genuine frustrations with plain SSRIs, and Forest Pharmaceuticals actually tried to engineer around it. That kind of mechanistic intentionality is worth acknowledging.

The problem is that the clinical payoff was modest. The faster-onset hypothesis showed up in some trial data but hasnt become a defining feature of how clinicians actually use the compound. The PETAL studies and subsequent Phase 3 work confirmed MDD efficacy — theres no question it works — but the differentiation story got muddier after vortioxetine arrived in 2013 with an even broader receptor profile (SERT, 5-HT1A, 5-HT1B, 5-HT3, 5-HT7) and a more compelling case for cognitive symptom improvement. At that point, vilazodone became the simpler version of the multi-target antidepressant concept rather than its leading example.

From a bench perspective, vilazodone does carry real value as a reference probe. If you’re designing experiments to dissect combined SERT inhibition plus 5-HT1A partial agonism — specifically trying to separate those two contributions to a behavioral or molecular endpoint — vilazodone gives you a clean, well-characterized tool with published pharmacokinetics and known receptor affinities (SERT Ki ~0.1 nM, 5-HT1A Ki ~0.2 nM, intrinsic activity ~70%). Thats not nothing. The CYP3A4 metabolism and the food-effect on bioavailability are well-documented, which makes dosing in animal models somewhat more predictable.

What we dont think is that vilazodone represents a current research priority. The antidepressant mechanism space has moved on. The interesting questions now involve psychoplastogens, BDNF-TrkB direct agonism, AMPA potentiation, and neuroinflammatory targets. Vilazodone is an approved drug, which means its evidence base is solid, but solid evidence on a mature mechanism in a saturated class isnt the same as a compelling research target. For investigators specifically studying 5-HT1A partial agonism pharmacology, it remains a useful reference. For everyone else, its a clinical compound that belongs in formularies, not on the short list of compounds worth bench time in 2025.

Honestly, the score of 50 reflects exactly what it is: competent, approved, well-understood, and no longer at the frontier of anything.

Novelty

28

Mechanism promise

55

In-category differentiation

40

Evidence quality

72

Translational signal

65

Research bench value

45

Rationale Vilazodone’s combined SERT + 5-HT1A partial agonism is genuine pharmacological thinking and the rubric explicitly places dual SERT/5-HT1A in the 50-70 mechanism range, but its novelty is low as a 2011-approved drug with mature literature, and vortioxetine has meaningfully outpaced it on multi-receptor differentiation. Strong evidence quality from Phase 3 RCTs props the overall up, but this is not a frontier target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

SSRI + 5-HT1A partial agonist

A dual-mechanism antidepressant combining SSRI activity with 5-HT1A partial agonism intended to accelerate clinical response.

Abstract

Vilazodone (5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide; CAS 163521-12-8; molecular formula C26H27N5O2; molecular weight 441.53) is an SSRI plus 5-HT1A partial agonist developed at Merck KGaA and Forest Pharmaceuticals, approved by the FDA in 2011 under the trade name Viibryd. SERT affinity is approximately 0.1 nM; 5-HT1A affinity is approximately 0.2 nM (intrinsic activity approximately 70 percent), producing partial agonism at the autoreceptor. The dual mechanism was designed to bypass the autoreceptor desensitization period that delays SSRI response: by directly activating 5-HT1A receptors while blocking SERT, vilazodone aims to produce faster clinical effect. Real-world clinical trials have shown modest response acceleration. Plasma half-life is approximately 25 hours; metabolism is via CYP3A4 (primary). Approved for major depressive disorder. The compound is administered with food, which doubles bioavailability compared to fasted dosing. Used as a reference compound for 5-HT1A partial agonist plus SSRI pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-212Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Moclobemide

Plain-language summaryIntrigue 62 / 100

Moclobemide (Aurorix) was a major step forward in MAOI design: it blocks MAO-A reversibly rather than permanently, which means dietary tyramine can simply outcompete the drug at the enzyme rather than triggering a crisis. That eliminates the dreaded cheese-effect that has held the older MAOIs back for sixty years. Roche brought it to market in Europe in 1989 and in Canada in 1992, but it never received FDA approval in the US, partly because the company’s Phase 3 trials were not designed to American regulatory standards. Efficacy in depression and social anxiety is solid in European data, comparable to SSRIs. Without the FDA stamp it remains underused in North American practice, which is unfortunate because it is genuinely a more elegant drug than its first-generation predecessors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

42/100

Canonical RIMA reference probe with real MAO-A selectivity utility; clinical edge never materialized

Look, moclobemide had a real idea. Irreversible MAOIs work, but the tyramine interaction is a legitimate safety ceiling that limits who you can put on them. Roche’s morpholine benzamide solved that by binding MAO-A reversibly — tyramine from a meal can simply outcompete it, so the cheese reaction risk collapses. That was a clean piece of pharmacology, and it earned the drug approvals across Europe and Canada through the early nineties. Here’s the thing though: the tyramine story was supposed to be the commercial unlock and it wasnt. Head-to-head against TCAs, moclobemide comes out modestly inferior on efficacy endpoints in most published comparisons. It never crossed the FDA finish line. The class it defines — RIMAs — has stayed small and the compound itself has stayed niche.

The mechanism is single-enzyme inhibition. MAO-A selectivity is roughly 100:1 over MAO-B at low doses, which is clean but not exciting by 2026 standards. We’re scoring mechanism against a landscape that includes dual incretins, mitochondrial peptides, and NMDA channel allosteric modulators. Selective reversible inhibition of one well-mapped enzyme in a saturated antidepressant class just doesn’t move the needle. What you get is predictable: serotonin and norepinephrine accumulation through reduced oxidative deamination, half-life of one to four hours, CYP2C19 clearance, twice-daily dosing. Nothing here is opaque.

Where moclobemide earns its score is bench utility. If your research question involves parsing MAO-A vs MAO-B contributions to a phenotype, moclobemide is the tool. It lets you probe MAO-A selectively and reversibly in a way that neither the irreversible drugs nor the less selective agents allow. Wash-out is fast given the short half-life, which matters for crossover designs. We’d describe it as the selegiline counterpart for MAO-A work — not exciting in isolation, but the right instrument when the question specifically calls for it. The social anxiety disorder literature also gives it a respectable translational footprint; the human signal is genuine even if effect sizes are modest.

The differentiation score reflects its position as the canonical compound in a small class. There’s no meaningful RIMA competitor in active research use, which would normally be a strength, but here the class itself hasn’t grown. Toloxatone exists but never achieved the same uptake. So moclobemide defines its category by default. Honest assessment: if your research program isnt specifically about MAO-A biology or RIMA pharmacology, there are more interesting places to put your attention. For investigators who do need that probe, its actually quite useful. For everyone else, it’s a mature approved drug with a story that largely peaked in the nineties.

Novelty

22

Mechanism promise

25

In-category differentiation

48

Evidence quality

58

Translational signal

55

Research bench value

60

Rationale Moclobemide’s reversibility was genuinely innovative in 1989 but that innovation is now fully absorbed into pharmacology textbooks; efficacy trails TCAs, it never achieved FDA approval, and its primary value in 2026 is as the reference compound for MAO-A selectivity experiments. Bench value keeps the score from bottoming out, but near-zero novelty and a saturated mechanism ceiling keep it well below 50.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Reversible MAO-A inhibitor (RIMA)

A morpholine benzamide reversible inhibitor of MAO-A (RIMA); the first MAOI that does not require dietary tyramine restriction.

Abstract

Moclobemide (4-chloro-N-(2-morpholin-4-ylethyl)benzamide; CAS 71320-77-9; molecular formula C13H17ClN2O2; molecular weight 268.74) is a morpholine benzamide reversible inhibitor of MAO-A (RIMA) developed at Roche and approved in Europe (1989) and Canada (1992) under the trade name Aurorix; never FDA approved for the US market. Distinct from earlier MAOIs by reversible binding: tyramine and other dietary substrates can displace moclobemide from MAO-A, eliminating the requirement for tyramine restriction at typical clinical doses. MAO-A selectivity ratio is approximately 100:1 over MAO-B at low doses. Plasma half-life is 1 to 4 hours; the short half-life dictates twice-daily dosing. Hepatic metabolism via CYP2C19 is the primary clearance pathway. Approved for major depressive disorder and social anxiety disorder. The eliminated tyramine restriction has not produced the expected clinical takeoff: efficacy is modestly inferior to TCAs in head-to-head trials, and the drug remains a niche option. Used as the canonical RIMA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-228Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Carbamazepine

Plain-language summaryIntrigue 60 / 100

Carbamazepine (Tegretol) is a first-generation anticonvulsant from Geigy, synthesized in 1953 and FDA-approved in 1968. It blocks voltage-gated sodium channels much like lamotrigine and is broadly effective for partial seizures, trigeminal neuralgia (where it is first-line), and bipolar mania. Its big practical headache is potent induction of the liver enzyme CYP3A4, which means it accelerates the breakdown of many other drugs (oral contraceptives, warfarin, many antidepressants), creating constant interaction problems. It also induces its own metabolism, so doses often need to climb in the first few weeks. The active leftover is a structurally similar epoxide that contributes to both the therapeutic effect and the side effects. Aplastic anemia and Stevens-Johnson syndrome are rare but serious risks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

First-generation sodium channel blocker, proven and approved, long superseded as a novel research target

Look, carbamazepine is a 70-year-old drug that works. The mechanism, state-dependent voltage-gated sodium channel inhibition, was characterized decades ago and hasn’t gotten more interesting since. What carbamazepine does best is be reliable, and that reliability is precisely what limits its appeal as a live research target in 2024.

The evidence base is genuinely impressive, in the way that things that have been FDA-approved since 1968 tend to be. Hundreds of replicated trials for partial-onset seizures, tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania. The translational arrow points straight down from bench to clinic because that work was done half a century ago. We’re not learning new things about carbamazepine; we’re using what we already know.

The differentiation story is the hard part. Oxcarbazepine was developed specifically to strip out carbamazepine’s worst liabilities, the potent CYP3A4 induction that wrecks contraceptive coverage and immunosuppressant dosing, the aplastic anemia and agranulocytosis risk, the SJS/TEN exposure in HLA-B*1502 carriers. Lacosamide took the sodium channel story in a more selective direction with slow-inactivation preference. Lamotrigine achieved a cleaner dual-mechanism profile with a better tolerability envelope. Carbamazepine retains the reference iminostilbene label, and thats genuinely useful for comparative class pharmacology. But if youre designing a new research program on voltage-gated sodium channels, you probably dont open with this one.

Honestly, where it still earns real bench credit is narrow but real. The auto-induction kinetics are a legitimate research model: the half-life collapses from 25-65 hours at first dose to 12-17 hours at steady state as it induces its own CYP3A4-mediated clearance, which makes it one of the cleaner in vivo models for studying auto-induction biology. The HLA-B*1502 pharmacogenomics work around SJS/TEN prediction in East and Southeast Asian populations is live research, and carbamazepine is the reference exposure for those studies. Those are real questions. They’re just not the kind of questions that drive high-priority bench allocations.

We think this belongs in the library as a reference standard and a pharmacogenomics model, not as a compound with active research momentum. A serious investigator looking for fresh signal in sodium channel pharmacology, CNS excitability, or mood stabilization would not prioritize carbamazepine in 2024. The science is largely settled. The score reflects that.

Novelty

12

Mechanism promise

20

In-category differentiation

28

Evidence quality

78

Translational signal

72

Research bench value

45

Rationale Carbamazepine scores high on evidence and translational signal because it is a fully approved drug with massive clinical literature, but novelty and mechanism promise are floor-level for a 1953 compound with a well-mapped, single-channel mechanism that newer agents have largely refined away. The reference probe angle gives it modest bench value, but this is not a compound generating new science.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Iminostilbene voltage-gated sodium channel blocker

A first-generation iminostilbene anticonvulsant and mood stabilizer with potent CYP3A4 induction.

Abstract

Carbamazepine (5H-dibenzo[b,f]azepine-5-carboxamide; CAS 298-46-4; molecular formula C15H12N2O; molecular weight 236.27) is an iminostilbene anticonvulsant developed by Walter Schindler at Geigy in 1953 and approved by the FDA in 1968 under the trade name Tegretol. Mechanism: state-dependent voltage-gated sodium channel inhibition (similar to lamotrigine), producing reduced neuronal hyperexcitability in seizure foci. Active metabolite carbamazepine-10,11-epoxide retains anticonvulsant activity. Plasma half-life is 25 to 65 hours initially but auto-induces own metabolism, dropping to 12 to 17 hours at steady state. Strong CYP3A4 induction produces clinically significant interactions with hormonal contraception, immunosuppressants, anticoagulants, antiretrovirals, and many other drugs. Approved for partial-onset and generalized tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania (in combination products). The principal safety concerns are aplastic anemia and agranulocytosis (rare but serious; HLA-B*1502 association predicts SJS/TEN risk in Asian populations and is screened pretreatment). Used as the reference iminostilbene voltage-gated sodium channel blocker.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-244Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Ostarine (MK-2866)

Our opinion on this compoundEstablished workhorse

39/100

Prototype SARM with the strongest human trial record in its class, but a failed phase 3 and a crowded successor field cap its research appeal

Look, Ostarine occupies a weird position in the SARM landscape. It was the first non-steroidal aryl propionamide to reach serious clinical evaluation, the proof-of-concept that tissue-selective androgen receptor agonism was achievable without the full androgenic liability of testosterone. That mattered enormously in 2005. In 2026, its prototype status is mostly a historical footnote.

The mechanism story is genuinely elegant, and we should credit it. Differential coactivator and corepressor expression across tissue types means the same ligand-receptor complex produces different conformational changes in skeletal muscle versus prostate. Ostarine exploits that. The pharmacology is clean, oral bioavailability is high, and the 24-hour half-life supports once-daily dosing in preclinical protocols. For a researcher setting up a model of tissue-selective AR biology, it remains a credible probe. Thats the bench value argument and its real, if modest.

The clinical record is where things get complicated. Phase 2 data from the GTx cachexia and stress urinary incontinence programs showed genuine lean mass accretion and some bone density signal. Those results were real enough to license to Merck and push to phase 3. Then the POWER trial happened. In 2013, enobosarm failed to meet its primary endpoints in cancer-associated muscle wasting despite what looked like a clean phase 2 story. The failure wasnt a mechanism disproof, but it did deflate the primary translational thesis and the compound has sat in a regulatory limbo ever since, no approval pathway, WADA-banned, and commercially gray-market.

What we dont like: the class has moved on. LGD-4033 hits harder. RAD-140 has a better anabolic-to-androgenic ratio in most model systems. Newer investigational SARMs have more interesting selectivity profiles and some have more recent human PK data. Ostarine is the weakest member of a class that now has stronger options, which tanks its differentiation score significantly. You can argue it has the cleanest human safety profile because its the least potent, but that argument only holds if you actually want a weak SARM, which most investigators don’t.

Where Ostarine still earns its place in a research library is as a reference comparator. Any serious SARM study needs a benchmark, and Ostarine is the most characterized option for that role. The hepatic enzyme elevation and HPG suppression signals at supratherapeutic doses are documented well enough to design around. For comparative mechanistic work on AR coactivator biology, the existing PK and safety data saves setup time. Honestly though, if your research question is about anabolic selectivity at the frontier of the field, there are better compounds to anchor a program around right now.

Novelty

22

Mechanism promise

42

In-category differentiation

32

Evidence quality

58

Translational signal

42

Research bench value

48

Rationale Ostarine scores reasonably on evidence because it is the most human-trialed SARM by a wide margin, but novelty and differentiation drag the composite down hard: the compound is 20-plus years old, the tissue-selective AR mechanism is now textbook, and the 2013 POWER trial failure for cancer cachexia weakened the primary translational story. More potent and more selective SARMs have entered the literature since, leaving Ostarine as a historical reference compound rather than a live frontier target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective androgen receptor modulator (non-steroidal)

A selective androgen receptor modulator developed for cachexia and muscle wasting; the prototype SARM and the most thoroughly characterized in human trials.

Abstract

Ostarine (Enobosarm, MK-2866, GTx-024; CAS 841205-47-8; molecular formula C19H14F3N3O3; molecular weight 389.33) is a selective androgen receptor modulator (SARM) developed at GTx Inc. (later licensed to Merck). The compound is a non-steroidal aryl propionamide that binds the androgen receptor (AR) with tissue-selective agonism: full agonist activity in skeletal muscle and bone, partial or absent activity in prostate and sebaceous glands. The selectivity arises from tissue-specific differences in AR coactivator and corepressor expression and from differential conformational induction by non-steroidal versus steroidal ligands. Phase 2 trials in cancer cachexia and stress urinary incontinence demonstrated lean body mass gains and bone density improvements, but a definitive phase 3 trial in cancer cachexia (POWER) failed to meet primary endpoints in 2013. The compound retains significant academic interest as a SARM prototype and is widely used recreationally (banned by WADA in sport) despite no regulatory approval. Plasma half-life is approximately 24 hours; oral bioavailability is high. The principal safety concerns are hepatic enzyme elevation and HPG axis suppression at supratherapeutic doses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-261Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 34 35 36 37 38 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.